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AbstrAct
Objectives Advancing the field of point-of-care testing 
(POCT) for STIs can rapidly and substantially improve STI 
control and prevention by providing targeted, essential 
STI services (case detection and screening). POCT 
enables definitive diagnosis and appropriate treatment in 
a single visit and home and community-based testing.
Methods Since 2014, the WHO Department of 
Reproductive Health and Research, in collaboration 
with technical partners, has completed four landscape 
analyses of promising diagnostics for use at or near 
the point of patient care to detect syphilis, Neisseria 
gonorrhoeae, Chlamydia trachomatis, Trichomonas 
vaginalis and the human papillomavirus. The analyses 
comprised a literature review and interviews. Two 
International Technical Consultations on STI POCTs (2014 
and 2015) resulted in the development of target product 
profiles (TPP). Experts in STI microbiology, laboratory 
diagnostics, clinical management, public health and 
epidemiology participated in the consultations with 
representation from all WHO regions.
results The landscape analysis identified diagnostic 
tests that are either available on the market, to be 
released in the near future or in the pipeline. The TPPs 
specify 28 analytical and operational characteristics of 
POCTs for use in different populations for surveillance, 
screening and case management. None of the tests that 
were identified in the landscape analysis met all of the 
targets of the TPPs.
conclusion More efforts of the global health 
community are needed to accelerate access to affordable 
quality-assured STI POCTs, particularly in low- and 
middle-income countries, by supporting the development 
of new diagnostic platforms as well as strengthening the 
validation and implementation of existing diagnostics 
according to internationally endorsed standards and the 
best available evidence.
IntrOductIOn
STIs, including HIV, continue to be a significant 
global public health issue. The WHO estimated 
357 million new cases of four curable STIs caused 
by: Treponema pallidum (syphilis) (6 million), Chla-
mydia trachomatis (CT) (131 million), Neisseria 
gonorrhoeae (NG) (78 million) and Trichomonas 
vaginalis (TV) (143 million).1 In addition, more 
than 290 million women are infected with the 
human papillomavirus (HPV).2 
Curable STIs continue to be a high burden on 
global health even though, in most cases, they can 
be treated with a single-dose antibiotic cure. WHO 
has estimated that about 1.86 million cases of 
syphilis occur worldwide among pregnant women 
each year, many of whom are either untreated or 
inadequately treated.3 Untreated maternal syphilis 
is believed to cause more than 500 000 perinatal 
deaths (ie, deaths that occur from 22 weeks’ gesta-
tion through the first seven days of life) each year.4i 
In addition, about 220 000 children became newly 
infected with HIV in 2014, making up more than 
10% of the total number of new HIV infections.5
Reliable, affordable diagnostic tests are key 
components of effective STI control and preven-
tion, their absence is an obstacle to reducing the 
STI burden. With some exceptions, the existing 
diagnostics for these STIs are laboratory-based 
platforms, which typically require a robust labo-
ratory infrastructure and well-trained laboratory 
technicians.6 In addition, turnaround time is often 
long, requiring patients to return for test results 
on a subsequent clinic visit. This often leads to 
significant loss to patient follow-up. Therefore, 
while these laboratory-based diagnostics are effec-
tive, they may not always be suitable for use in 
resource-limited settings where diagnostic access to 
and delivery of appropriate diagnostics can be chal-
lenging. This is important, since 80%–90% of the 
global STI burden occurs in the developing world.7
One of the major barriers to advancing the field 
of diagnostic tests for STIs is the absence of reliable, 
low-cost, point-of-care tests (POCTs). These tests 
offer immediate results allowing patients to receive 
diagnosis and treatment in one, and possibly the 
only, visit. POCTs are often equipped with readers 
that enable data transmission, offering the potential 
for improved STI surveillance and facilitating all 
aspects of effective STI control.8
The WHO Global Health Sector Strategy on 
Sexually Transmitted Infections, 2016–2021, high-
lights POCT as one of the innovations to accelerate 
universal health coverage, emphasising discovery, 
development and rapid uptake, complemented with 
research to optimise implementation and impact of 
these STI POCTs.9
i This compares to annual death rates for other important 
infections in pregnancy, such as HIV, which is estimated 
to cause between 250 000 and 290 000 perinatal deaths 
worldwide, and malaria in pregnancy, which is estimated 
to cause about 200 000 perinatal deaths.4
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In 2006, WHO introduced the ASSURED criteria for POCTs 
for use at the level 1 health centre: Affordable, Sensitive, Specific, 
User-friendly, Rapid and robust, Equipment-free and Deliverable 
to end-users. Although notable progress has been made in devel-
oping diagnostic tests for syphilis, chlamydial and gonococcal 
infections, and trichomoniasis,10–14 there are still no tests avail-
able that comply with all these criteria.
To accelerate advancements in the field of STI POCT, WHO 
facilitated landscape analyses of potential point-of-care diag-
nostic technologies for dual HIV/syphilis tests, CT, NG, TV and 
HPV, available and in the pipeline. It concurrently organised 
expert meetings to conceive target product profiles (TPP) for 
POCTs for these infections. This article describes the processes 
and results of these two initiatives and considers whether the 
current diagnostic pipeline is adequate following the TPPs.
MethOdOlOgIes
The landscape analysis was conducted through both primary 
and secondary sources. The secondary sources included (1) 
published literature; (2) published and unpublished reports; (3) 
WHO policies; and (4) websites of diagnostic manufacturers and 
developers. For the literature review, the following databases 
were searched—PubMed, Scopus and Web of Science using the 
terms ‘test’, ‘testing’, ‘performance’ and ‘diagnosis’ together 
with ‘sexually transmitted infection’, ‘human immunodeficiency 
virus’, ‘HIV’, ‘syphilis’, ‘Chlamydia trachomatis’, ‘Neisseria 
gonorrhoeae’, ‘Trichomonas vaginalis’, ‘human papillomavirus’ 
and ‘HPV’. Additional web sources, including Google, were 
also searched to identify diagnostic platforms and tests for 
STIs. Additional reviews of published literature informed on 
the performance and operational characteristics of these tests 
and indicated when independent performance data were not 
available. To deepen the landscape analysis, primary sources 
were also used. Informal telephone interviews were conducted 
with representatives from the companies/developers of interest. 
Questions, tailored to the individual company/developer, were 
generally of a technical nature about the diagnostic platform/
test(s), and in the case of platforms in the pipeline, they also 
included inquiries about the development path for the plat-
form/test(s) and expected commercial launch. Summaries of 
each platform/test were written and reviewed for accuracy with 
representatives from the company/developer associated with 
the platform/test. The first landscape analysis was conducted 
in early 2014 to inform the first WHO Technical Consultation 
on STI POCT in May 2014.15 The landscape was updated in 
2015 prior to the second WHO Technical Consultation on STI 
POCT. The third update was completed in December 2016. The 
analysis was conducted through an iterative process as part of 
efforts to address the ever-evolving and dispersed nature of the 
field of POCT.
The development of the TPPs was initiated through reviewing 
the pooled performance data from systematic reviews commis-
sioned by WHO, published predictive models to inform test 
performance, and the lower limits of detection of technologies 
identified in the landscape analyses and then further developed 
through a series of face-to-face and online consultations with 
an international expert group (IEG) using an adapted Delphi 
methodology. The initial list of 28 parameters for the TPPs was 
adapted from the TPP for dual HIV/syphilis tests commissioned 
in 2013 by UNITAID.16 The intended use and target populations, 
sexually active with a focus on STI clinic attendees, pregnant 
women, men who have sex with men (MSM) and sex workers 
(SW), were selected according to the current international 
guidelines for STI surveillance, case management and screening 
programmes for syphilis, NG, CT, TV and HPV.17–23 TPP param-
eters were expressed as minimal and optimal recommendations, 
in order to reflect the range of needs of healthcare providers and 
patient populations within the intended use of the tests using a 
public health approach.
The IEG consisted of 32 internationally recognised STI experts, 
including clinicians, microbiologists, professionals in the field of 
laboratory medicine, public health, social science, and diagnostic 
technology and development, from all WHO regions. The IEG 
also comprised representatives from WHO, UNITAID, and the 
Foundation for Innovative New Diagnostics (FIND). All experts 
were assessed for conflicts of interest, none were found.
At the first meeting in May 2014, the group assessed and 
endorsed the list of TPP parameters. Small group work resulted 
in the first draft TPPs for each of the POCTs to detect STIs. 
The draft TPPs were then discussed with all the participants and 
reconciled according to the feedback, taking into consideration 
agreements and disagreements between the small groups and the 
plenary. During both the small group and plenary sessions, the 
first STI diagnostic landscape was used as a reference by partici-
pants, allowing them to compare proposed minimal and optimal 
TPP characteristics with those of existing STI tests. Because of 
the oncogenicity of the pathogen, the proposed TPPs for POCTs 
to detect HPV were reviewed by professional  associations.ii The 
refined TPPs were then presented and reviewed at the second 
technical consultation in July 2015. All comments and points 
discussed during the second expert group meeting were docu-
mented and reflected in the revised TPPs as a consensus-based 
agreement among all stakeholders. The IEG assessed and 
endorsed the TPP parameters through several rounds of online 
consultations. The final TPPs were consolidated and published 
on the WHO website, http://www. who. int/ reproductivehealth/ 
topics/ rtis/ pocts/ en/.
results
syphilis
Landscape
A range of POCTs for syphilis has been developed. These tests 
are antibody tests that detect treponemal (TP) antibodies. Among 
these are tests from Alere (Alere Determine), Alere/Standard 
Diagnostics (SD Syphilis 3.0), The Tulip Group/Qualpro (Syph-
icheck-WB) and Omega Diagnostics (Visitect Syphilis), OnSite 
Syphilis Ab Combo Rapid Test (CTK Biotech), Syphilis Health 
Check (Trinity Biotech) and Uni-Gold Syphilis Treponemal 
(Trinity Biotech). Of these tests, all but Syphilis Health Check 
are CE-IVD marked; Syphilis Health Check is approved by the 
US Food and Drug Administration (FDA) and CLIA waived in 
the USA. These tests are summarised in table 1.
Historically, there have been concerns about the performance 
of TP POCTs. However, a recent meta-analysis on the perfor-
mance of Alere Determine Syphilis TP, SD Syphilis 3.0, Syph-
icheck WB and Visitect Syphilis demonstrated sensitivity and 
specificity estimates comparable to laboratory-based tests.17 Test 
performance, from which the authors conclude that the tests are 
useful in resource-constrained settings where access to labora-
tory testing for syphilis is limited, is summarised in table 2.
There are no peer-reviewed evaluations of the Uni-Gold 
Treponemal test, but independent reviews demonstrated good 
ii American Cancer Society, Basic Health International, Global Coalition 
Against Cervical Cancer (GC3), Preventive Oncology International.
group.bmj.com on January 4, 2018 - Published by http://sti.bmj.com/Downloaded from 
S71Toskin I, et al. Sex Transm Infect 2017;93:S69–S80. doi:10.1136/sextrans-2016-053071
Original article
sensitivity and specificity for both the OnSite Syphilis Ab Combo 
Rapid Test and the Syphilis Health Check tests.18 19
It should be noted that the TP POCTs described above cannot 
be used to distinguish between active and past treated infections 
due to the persistence of TP antibodies. In resource-limited 
settings, where many people do not have access to laborato-
ry-based non-TP tests for confirmation of active syphilis, preg-
nant women who are found to be seropositive with a TP POCT 
are treated for syphilis in order to prevent any possibility of 
transmission of the infection.
This highlights the need for a combination TP/non-TP test 
that can be used to diagnose syphilis at the point of care (POC). 
The DPP Syphilis Screen & Confirm Assay (Chembio Diag-
nostic Systems) is such a test. It requires a sample size of only 
10 µL of whole blood (fingerstick or venepuncture), and tests 
can be stored at room temperature (2°C–30°C). The turnaround 
time of the test is 15–20 min. The test has been shown to be 
highly sensitive and specific, and also useful for the serological 
diagnosis of syphilis in primary healthcare clinics or resource-
poor settings.20 21 Performance of the assay from three evalua-
tions is summarised in table 3. Although conducted using varying 
methodologies and samples, each of the studies concluded that 
the DPP Screen & Confirm Assay could be useful for diag-
nosing syphilis in primary healthcare settings in resource-limited 
settings.
In a laboratory-based evaluation using banked serum samples 
conducted by Castro et al the DPP TP and non-TP lines were 
compared with the Treponema pallidum particle agglutina-
tion (TPPA) assay and a quantitative rapid plasma regain (RPR) 
test, respectively.20 Yin et al conducted a multicentre field eval-
uation in China.21 Three kinds of specimens (whole blood, 
finger prick blood and blood plasma) were used; reference 
standards were the TPPA assay for the TP test and the toluidine 
red unheated serum test for the non-TP test. Lastly, the study by 
Causer et al was again laboratory-based and used serum samples. 
It compared the TP and non-TP test lines with immunoassays 
table 1 Selected POCTs for detection of syphilis: summary of selected operational characteristics from product inserts
test
(manufacturer) specimen
Volume of whole blood or 
other specimen time to result (min) test type
Alere Determine
Syphilis TP
Alere (USA)
Whole blood (fingerstick), plasma or serum 50 µL 15 min (up to 24 hours) Lateral flow strip
SD Syphilis 3.0
Alere/SD Bioline (South Korea)
Whole blood (venous or fingerstick), plasma 
or serum
20 µL (whole blood)
10 µL (plasma or serum)
5–20 min Cassette enclosed test card
Syphicheck-WB
The Tulip Group/Qualpro (India)
Whole blood (venous or fingerstick), plasma 
or serum
25 µL 15 min Cassette enclosed test card
Visitect Syphilis
Omega Diagnostics (UK)
Whole blood (venous or fingerstick), plasma 
or serum
50 µL 30 min Cassette enclosed test card
OnSite Syphilis Ab Combo Rapid Test
CTK Biotech (USA)
Whole blood (venous or fingerstick) 1 drop 15 min Cassette enclosed test card
Syphilis Health Check
Trinity Biotech (Ireland)
Whole blood (fingerstick), plasma or serum 2 drops 10 min Cassette enclosed test card
Uni-Gold Syphilis Treponemal
Trinity Biotech (Ireland)
Whole blood (venous or fingerstick), plasma 
or serum
~60 µ ~15 min Cassette enclosed test card
POCTs, point-of-care tests.
table 2 Meta -analysis data on performance of select TP POCTs for syphilis
POct sample Parameters Assuming imperfect reference standards (95% crl)*
Alere Determine Serum Sensitivity 90.04% (80.45, 95.21)
Specificity 94.15% (89.26, 97.66)
Whole blood Sensitivity 86.32% (77.26, 91.70)
Specificity 95.85% (92.42, 97.74)
SD Syphilis 3.0 Serum Sensitivity 87.06% (75.67, 94.50)
Specificity 95.85% (89.89, 99.53)
Whole blood Sensitivity 84.50% (78.81, 92.61)
Specificity 97.95% (92.54, 99.33)
Syphicheck-WB Serum Sensitivity 74.48% (56.85, 88.44)
Specificity 99.14% (96.37, 100.0)
Whole blood Sensitivity 74.47% (63.94, 82.13)
Specificity 99.58% (98.91, 99.96)
Visitect Syphilis Serum Sensitivity 85.13% (72.83, 92.57)
Specificity 96.45% (91.92, 99.29)
Whole blood Sensitivity 74.26% (53.62, 83.68)
Specificity 99.43%, (98.22, 99.98)
Adapted from Jafari et al.17
*Adjustments were made for imperfect reference standards using the Bayesian hierarchical summary receiver operating characteristic curve method. The results are point 
estimates of sensitivity and specificity for each test, using serum and whole blood, around a 95% credible interval (as opposed to a CI).
Crl, credible interval; NA, not available; POCT, point-of-care testing; TP, treponemal.
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and RPR as reference standards, respectively.22 Results of the 
studies are summarised in table 3.
Target product profile
The IEG agreed that the main goals of POCTs for syphilis is 
to detect T. pallidum, TP antibodies and non-TP antibodies. 
The agreed intended use was surveillance and case management 
among the sexually active population, including key populations 
(MSM, SW and STI clinic/service attendees), as well as screening 
of pregnant women and key populations. The results of the tests 
are expected to be quantitative (clear reactive, non-reactive or 
invalid) with minimal instructions for interpretation. A finger 
prick capillary blood, maximum 50 µL with no more than one 
operator step as a minimal and 20 µL integrated specimen prepa-
ration as optimal specimen characteristic, was agreed by the 
experts (table 4).
With regard to the clinical sensitivity of the TP component, a 
level of >80% as minimally acceptable and a level of >90% as 
optimal were endorsed by the IEG. Regarding the clinical spec-
ificity, the endorsed levels were >90% and >95%, respectively. 
For the non-TP component, the agreed minimal level of clin-
ical sensitivity were >95% of high titre (1 in 8) and >99% of 
high titre (1 in 8) as optimal level, the endorsed levels of clin-
ical specificity were >80% (minimal) and >95% (optimal), 
respectively.
One of the critical characteristics of a POCT is the time to result, 
which is the time between sample collection and processing and 
getting the result. The IEG agreed that the minimal acceptable 
time to result for an ideal POCT for syphilis is up to 60 min, and 
the optimal turnaround time should be 30 min or shorter. This 
recommendation is based on the currently available diagnostic 
technology, which is primarily lateral flow chromatography, as 
well as clinical practice with regard to syphilis case management 
and screening programmes, including in rural and remote areas 
with limited or no access to laboratory-based diagnostics. It was 
also agreed by the IEG that the POC diagnostic platform should 
have connectivity capability as a minimal TPP characteristic in 
order to support surveillance and monitoring activities within the 
syphilis control programmes.8 The IEG has also recommended 
the minimal acceptable target price per test as <US$3 (excluding 
the cost of a device or reader) and <US$1.5 as the optimal target 
price per test. The target prices were recommended according to 
the analysis of the current market as well as the WHO procure-
ment mechanisms established for some diagnostic tests to detect 
syphilis.
C. trachomatis, N. gonorrhoeae
Landscape
The current POCTs for both CT and NG are immunoas-
says to detect antigen.23–25 Systematic reviews of their perfor-
mance showed pooled sensitivities of less than 50% for vaginal 
swabs compared with NAATs as reference standards.26 27 
Improved assays are required, especially for women, for whom 
the syndromic approach to managing vaginal discharge is 
inadequate.28
There is currently one NAAT-based platform, the GeneXpert 
system manufactured by Cepheid, that is available for near-pa-
tient diagnosis of CT, NG and CT/NG combined. The GeneX-
pert is a fully automated and integrated, polyvalent system for 
PCR-based NAAT that allows random access so that assays for 
detection of different pathogens can be performed at the same 
time. The assay may be used on the following specimens from 
both asymptomatic and symptomatic patients: female and male 
urine, endocervical swabs collected in a clinical setting, including 
patient-collected vaginal swabs.
The GeneXpert system integrates and automates sample prepa-
ration, amplification and detection in a single-use, self-contained 
cartridge. The performance of the Xpert CT/NG assay has been 
evaluated and found to be very good relative to established labo-
ratory-based assays.29–31
CT, NG and CT/NG platforms/assays in the pipeline
The main characteristics of POCTs and near-to-patient diag-
nostic platforms in the pipeline are presented in table 5.
Target product profile
With respect to POCTs to detect NG and CT, the IEG discussed 
the main performance and operational characteristics of 
combined and mono-POCTs. Table 6 and 7 present the agreed 
minimal and optimal characteristics. The intended use of desired 
POCTs for both infections is the same as for syphilis, that is, 
surveillance and case management of NG and CT in sexually 
active populations as well as screening for asymptomatic infec-
tions in key populations, particularly MSM and SW at primary 
healthcare services or outreach, defined by the group as primary 
healthcare settings. The tests are expected to provide clear qual-
itative positive, negative or invalid results with minimal instruc-
tions by using vaginal swabs in women and urine in men as a 
minimally accepted specimen and urine in both men and women 
as well as vaginal self-collected specimen in women, and pharyn-
geal and rectal swabs, particularly for MSM. In order to address 
table 3 Performance of DPP Syphilis Screen & Confirm Assay (Chembio Diagnostics Systems)
study sample
Parameters % 
(95% cI) dPP treponemal line dPP non-treponemal line
Castro et al20 Banked serum 
samples
Sensitivity 96.5 (NA) 98.4 (NA)
Specificity 95.5 (NA) 98.6 (NA)
Yin et al21 Whole blood (n=1323) Sensitivity 96.7 (95.1–97.9) 87.2 (84.0–89.9)
Specificity 99.3 (98.3–99.7) 94.4 (92.6–95.8)
Finger prick blood (n=488) Sensitivity 96.4 (93.5–98.0) 85.5 (82.4–89.4)
Specificity 96.4 (93.5–98.0) 96.1 (92.9–97.9)
Blood plasma (n=1323) Sensitivity 94.6 (92.5–96.1) 88.4 (85.3–90.9)
Specificity 99.6 (98.7–99.9) 95.0 (93.3–96.3)
Causer et al22 Serum (n=1005) Sensitivity 89.8% (87.3–91.9) 94.2 (91.8–96.0)
Specificity 99.3% (97.0–99.9) 62.2 (57.5–66.6)
NA, not applicable.
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the needs for such diagnostics in rural areas, a single-use, biode-
gradable or recyclable disposable diagnostic test was preferred, 
optionally equipped with a reader (small, portable, tabletop or 
handheld) that does not require external power supply. The 
IEG recommended the following clinical performance charac-
teristics for ideal POCTs to detect genital gonococcal infection: 
sensitivity and specificity, 90% minimal and 98% optimal. The 
POCTs to detect genital chlamydial infection are expected to 
guarantee >90% sensitivity (minimal) and 100% (optimal). With 
regard to the specificity, the recommended values are 98% and 
100% as minimal and optimal, respectively.
The operational characteristics include training require-
ments, less than 90 min minimally and no more than 30 min 
optimally. For the time to results, the minimal was specified 
as less than 60 min and the optimal as 30 min or less either 
for separate or combined NG and CT diagnostic platforms. 
If diagnostic platforms are equipped with a reader, it should 
include a Global Positioning System (GPS) module. The 
minimal acceptable target price per test was <US$5 (excluding 
the cost of a device or reader) and <US$1 optimally.
t. vaginalis
Landscape
Diagnosis of TV infection in women has traditionally been 
performed by microscopy of vaginal secretions, but this technique 
requires immediate evaluation of a wet preparation and is only 
about 50% sensitive when compared with culture or NAAT.32 33 
Diagnosis of TV in men is typically from wet mount with micro-
scopic visualisation of the parasites on slide preparations from 
urethral secretions.32 Modern nucleic acid-based testing for TV in 
either men or women is convenient, accurate and more sensitive 
than traditional methods. Like testing for CT and NG, there are 
a number of reliable laboratory-based molecular systems for TV 
testing. 
In addition to these molecular tests, there is at least one 
rapid diagnostic test for detection of TV: the OSOM Trich-
omonas Test (Sekisui Diagnostics), an immunochromato-
graphic capillary-flow enzyme immunoassay dipstick test 
detecting TV antigen that has shown to perform reasonably 
well when compared with a combined reference standard of 
wet mount and culture and/or PCR.34 35 GeneXpert (Cepheid) 
table 4 TPP—combined TP and non-TP POCT for syphilis
Goal of test To detect TP-specific antibodies and non-TP-specific antibodies
Intended use and target patient* Surveillance/case management: sexually active population, including key populations (eg, MSM, SW, STI clinic/service 
attendees)
Screening: pregnant women, key populations
Target use setting To detect TP-specific antibodies and non-TP-specific antibodies
Results Clear reactive, non-reactive or invalid result with minimal instructions for interpretation
Equipment Single-use diagnostic test preferred, reader optional (small, portable, tabletop or handheld, no electricity/power supply 
required)
target use(s) tP component non-tP component
Reference technology TPPA RPR
Performance Minimal Optimal Minimal Optimal
Clinical sensitivity† >80% >90% >95% of high titre (1:8) specimens >99% of high titre (1:8) specimens
Clinical specificity >90% >95% >80% >95%
Quantitation‡ Not applicable
Key minimal and optimal operational characteristics for combined tP and non-tP POct for syphilis
Minimal Optimal
Specimen Finger prick capillary blood (maximum 
50 µL)
Finger prick capillary blood (maximum 20 µL)
Steps performed by healthcare worker between 
specimen preparation and result
No more than three operator steps 
that are not timed nor labour intensive
Maximum one operator step (none of which has a timed interval), excluding waste 
disposal
Training required <90 min 30 min
Time to result =60 min =30 min
Connectivity: device/reader If combined with a reader, reader has 
integrated GPS module.
If combined with a reader, internally integrated GPS/GPRS module and conformity 
with HL-7 messaging standards
Data export (for quality assurance): device/reader If combined with a reader, full data 
export over mobile phone network
 ► If combined with a reader, full data export over mobile phone network (data 
transmission can automatically select between GPRS or more advanced networks 
and GSM, based on available coverage).
 ► GPRS should be able to use the internet FTP to transmit data: data transfer should 
be initiated every 6–12 hours automatically by the reader; data can be exported 
in a format compatible with HL-7 standards, where appropriate; instrument tracks 
and transmits quality assurance data over time (eg, identify shifts or trends).
Target price per test (excluding the cost of a 
device or reader)§
<US$3 <US$1.5
*Should be guided by the knowledge of the local epidemics.
†Based on a sample size sufficient to achieve CIs of ±5% around a point estimate of sensitivity and specificity.
‡POCTs are only to provide a positive/negative result, other quantitative methods will be used for quantitation.
§It does not include the cost of device/reader in case the POCT is device based or/and requires a reader for the result.
FTP, File Transfer Protocol; GPRS, General Packet Radio Service; GPS, Global Positioning System; GSM, Global System for Mobile; MSM, men who have sex with men; POCT, point-
of-care testing; RPR, rapid plasma regain; SW, sex worker; TP, treponemal; TPP, target product profile; TPPA, Treponema pallidum particle agglutination.
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and Quidel (Quidel) have launched assays for TV, and Atlas 
Genetics has a TV assay in its development pipeline for 2017. 
These assays are described in table 8.
Target product profile
All experts agreed that the main intended use of a POCT to 
detect TV is surveillance and case management in the sexually 
active population, including key populations (female SWs and 
STI clinic attendees), mainly in primary healthcare settings. 
Vaginal swabs as minimal and urine as an optimal option, 
including self-collected samples, were recommended by the 
IEG to perform qualitative testing. The results should be ideally 
obtained through no more than three (minimal) or one (optimal) 
non-labour-intensive operator steps and with minimal instruc-
tions for interpretation. The POCTs to detect TV are expected 
to ensure 85% sensitivity for samples collected by clinicians as 
minimal and 98% with both clinician and self-collected samples 
as optimal value. Recommended specificity ranged from minimal 
99% to optimal 100%.
If the diagnostic platform is equipped with a universal reader, 
it should include a GPS module, but only as an optimal charac-
teristic of POCT. The training requirements, cost per test as well 
as time to result are the same as those recommended for POCTs 
to detect NG and CT. Such agreement among the assays should 
help align the introduction and testing procedures for all three 
infections within the context of case management in women.
human papillomavirus
Landscape
In the USA, the Papanicolaou (Pap) test has been the gold stan-
dard for detecting cervical cancer in women over 30 years of 
age, mostly caused by HPV. However, the FDA recently recom-
mended that the Cobas HPV Test (Roche) should be the first 
line of screening. HPV screening using either of these methods 
or using visual inspection with acetic acid (VIA) is difficult in 
resource-limited settings. The Cobas HPV Test, as other molecu-
lar-based tests must be performed in centralised laboratory facil-
ities using sophisticated instrumentation. However, Qiagen has 
also introduced a molecular HPV assay, the careHPV Test, that 
is designed for use in low-resource settings. Performance of the 
assay has been good relative to either the Pap test or VIA.36 37
Of the diagnostic platforms discussed earlier in this report, 
GeneXpert (Cepheid) has a commercially available HPV assay 
(characteristics summarised in table 9). Several peer-reviewed, 
published studies of the assay found strong performance relative 
to laboratory-based reference standards in women referred for 
colposcopy.38–41 Cepheid also has an HPV assay in the pipeline 
for its new, smaller Omni platform, which is likely to be on the 
market in 2018. No other viable pipeline assays were identified.
Target product profile
The TPPs for HPV combined and mono-POCTs are presented 
in table 10.
The IEG has also agreed to develop a stand-alone TPP for 
near-to-patient diagnostic platforms to detect HPV biomarkers 
(high-risk HPV (HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
59 and 68)) oncoprotein or correlated, related biomarker (e.g., 
quantitative mRNA) for anal or cervical specimens. The TPP can 
be found on the website of WHO.
With regard to the TPP for POCTs targeting high-risk HPV 
(16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), the 
expert group agreed that intended use should be screening in 
women between 30 and 64 years old and in HIV-positive women 
of all ages. The specimen should be provider-collected cervical 
or self-collected cervicovaginal (preferred because no need for 
speculum exam or clinic visit). The test should give a clear posi-
tive, negative or invalid result with minimal instructions for 
table 5 POC platforms—CT, NG and CT/NG: summary of selected analytical and operational characteristics
Company Cepheid Atlas Genetics Alere Molbio/bigTec Ustar
Assay name GeneXpert
CT, CT/NG
Atlas io
CT; CT/NG (pipeline)
Alere i
CT/NG (pipeline)
Truelab PCR
CT, NG (pipeline)
RT CPA HIV-1 Viral Load
CT (pipeline)
Use setting Tabletop, not portable
Level 2—district hospital
Tabletop; portable
Level 1—health centre
Tabletop; portable
Level 1—health centre
2 instruments; not 
portable; Level 2—district 
hospital
Level 2—district hospital
Specimen Female and male urine, 
endocervical swab/patient-
collected vaginal swab
Self-collected and clinician-
collected vaginal swabs 
from symptomatic and 
asymptomatic women, and 
urine from men
Female and male urine, 
endocervical swab/
patient-collected vaginal 
swab
TBD TBD
Steps ~4; sample preparation 
automated
~4; automated sample 
preparation on instrument
~6 simple steps; raw 
sample added to device
Multiple pipetting steps ~3–5 steps from sample 
to result
Time to result ~90 min 30 min <60 min
Cold chain; reagent 
stability
No; TBD Cartridges with reagents 
stable at 2°C–25°C
No; >12 months No; 3 months at 
temperatures to 40°C
Power Mains power required; solar 
power possible
Mains power required AC mains and DC from 
external AC/DC supplied 
plug pack
Rechargeable lithium ion 
battery
Mains power or 
rechargeable battery
Training Less than 0.5 day Less than 1 hour; no formal 
training required; self-
explanatory user guide and 
screens on instrument
Less than 0.5 day Less than 0.5 day Approximately 0.5 day
Connectivity Yes; computer/internet required; 
remote calibration
Yes; via middleware Yes; USB and Ethernet 
outlets
Yes; wireless connectivity Will be used with Genie 
device; TBD
Equipment cost (US$); per 
test cost
~$17 000 (with 4 modules), but 
could be higher; $16.20 (CT/NG)
TBD TBD ~$8000; TBD <$5000; TBD
AC, alternating current; CT, Chlamydia trachomatis; DC, direct current; NG, Neisseria gonorrhoeae; POC, point of care; TBD, to be determined.
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interpretation and there should be no more than three non-la-
bour-intensive steps minimally and one optimally. The required 
training should be maximum 90 min and optimally maximum 
30 min. Time to results should be one hour or less as minimal 
option and less than 30 min as optimal. The sensitivity has to 
be 85% minimally and 95% optimally, and for specificity no 
consensus was reached. If the diagnostic platform is equipped 
with a universal reader, it should include a GPS module and 
ideally be conform with HL-7 messaging standards. The cost per 
test has been set to maximum US$3 and optimally not more than 
US$1.5.
next-generation technologies
In addition to the platforms described above that use conven-
tional lateral flow and molecular techniques, some diagnostic 
platforms use what might be described as ‘next-generation’ tech-
nologies. The development of techniques that permit microscale 
fabrication and processing methods using silicon and the 
advances in plastics engineering can facilitate mass-produced, 
low-cost, ultraportable instrumentation with sophisticated 
sample and information processing capabilities that can be used 
effectively in diagnostics for use at the POC.42 Some of these are 
discussed below.
Microscale and nanoscale detection technologies
Demonstrable progress has been made in micro- and nanotech-
nologies for disease detection. These technologies can categorised 
as: optical and non-optical methods of detection. Non-optical 
detection methods, including electrical impedance sensing, are 
attractive for their simplicity; while optical sensing methods, 
once thought to be too costly, cumbersome and not sufficiently 
robust, are being aided by the latest advances in camera technol-
ogies, which put increasingly sophisticated imaging ability into 
smartphones. Cellphone technologies are already being used for 
diagnostic applications.
Optical methods of detection
Some of the most common optical detection methods are fluo-
rescence, absorbance and chemiluminescence.43 Of these, 
fluorescence is most often used in diagnostics, including in 
table 6 TPP—combined/monogonococcal infection test
Goal of test To detect NG
Intended use and target patient* Surveillance/case management: sexually active population, including key populations (eg, MSM, SW, STI clinic/service attendees)
Screening/regular testing: key populations
Target use setting Healthcare settings particularly at primary care level (level 1) or above
Results Clear positive, negative or invalid result with minimal instructions for interpretation
Equipment Single-use, biodegradable or recyclable disposable diagnostic test preferred, reader optional (small, portable, tabletop or handheld, no 
electricity/power supply required)
target use(s) gonorrhoea testing patient with stI
Reference technology Laboratory-based NAAT
Performance Minimal Optimal
Clinical sensitivity† 90% (genital) 98% (genital)
Clinical specificity 90% (genital) >98% (genital)
Quantitation‡ Not applicable
Key minimal and optimal operational characteristics for gonococcal infection test
Minimal Optimal
Specimen§ Vaginal fluid in women and 
urine in men
Urine in men and women, vaginal, rectal and pharyngeal
Steps performed by healthcare worker between 
specimen preparation and result
No more than three operator 
steps that are not timed nor 
labour intensive
One operator step (none of which has a timed interval), excluding waste disposal
Training required <90 min 30 min
Time to result =60 min =30 min
Connectivity: device/reader If combined with a reader, reader 
has integrated GPS module.
If combined with a reader, internally integrated GPS/GPRS module and conformity with HL-7 
messaging standards
Data export (for quality assurance): device/reader If combined with a reader, full 
data export over mobile phone 
network
 ► If combined with a reader, full data export over mobile phone network (data 
transmission can automatically select between GPRS or more advanced networks and 
GSM, based on available coverage).
 ► GPRS should be able to use the internet FTP to transmit data: data transfer should 
be initiated every 6–12 hours automatically by the reader; data can be exported in 
a format compatible with HL-7 standards, where appropriate; instrument tracks and 
transmits quality assurance data over time (eg, identify shifts or trends).
Target price per test (excluding the cost of a 
device or reader)¶
<US$5 <US$1
 *Should be guided by the knowledge of the local epidemics.
†Based on a sample size sufficient to achieve CIs of ±5% around a point estimate of sensitivity and specificity.
‡POCTs are only to provide a positive/negative result, other quantitative methods will be used for quantitation.
§Sensitivity and specificity for rectal and pharyngeal swabs are not yet determined.
¶It does not include the cost of device/reader in case the POCT is device based or/and requires a reader for the result.
FTP, File Transfer Protocol; GPRS, General Packet Radio Service; GPS, Global Positioning System; MSM, men who have sex with men; NG, Neisseria gonorrhoeae; POCT, point-of-
care testing; SW, sex worker; TPP, target product profile.
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microscopy, flow cytometry and PCR. Microscale approaches 
often use fluorescence detection, frequently incorporating a 
laser or light-emitting diode (LED) for excitation of the tag. For 
example, fluorescence microscopy has been a standard method for 
detecting Mycobacterium (tuberculosis) in sputum samples. More 
recently, LED-based microscopy has increased access to microscopy 
in resource-limited settings. Fluorescence is also commonly used as 
an indicator in NAAT-based testing, either as a DNA intercalating 
dye or as part of a fluorophore-quencher system conjugated to 
probe DNA.
Chemiluminescence techniques are also being used in diag-
nostics for POC. Colorimetry has the advantage of providing 
a signal that is visible to the naked eye, which can eliminate 
the need for cameras in tests. Drawbacks include that instru-
ment-based analysis of colorimetric signals is not as precise as 
other methods. An example of a microfluidics-based technology 
using colorimetry is the patterned paper technology from Diag-
nostics for All. The technology patterns channels and assay zones 
(or wells) of water-repellent materials into a piece of paper about 
the size of a postage stamp.
Non-optical methods of detection
In addition to optical methods of detection, there are also 
non-optical methods. Although electrical sensing techniques are 
frequently simpler and less expensive than optical methods, the 
downside is that they typically rely heavily on sample processing 
steps to remove background noise.
One electrical sensing method that has shown promise is imped-
ance spectroscopy, typically using microfabricated electrodes, 
which measures electrical impedance of an aqueous solution as a 
function of alternating current frequency. Several applications in 
CD4 cell counting have been developed,44 45 and impedance-based 
cell counting approaches have also been used in the context of 
malaria diagnosis.43 44 Some commercial applications are already 
emerging.
table 7 TPP—combined/monochlamydial infection test
Goal of test To detect CT
Intended use and target patient* Surveillance/case management: sexually active population, including key populations (eg, MSM, SW, STI clinic/service attendees)
Screening/regular testing: under age of 25 years and key populations
Target use setting Healthcare settings particularly at primary care level (level 1) or above
Results Clear positive, negative or invalid result with minimal instructions for interpretation
Equipment Single-use, biodegradable or recyclable disposable diagnostic test preferred, reader optional (small, portable, tabletop or 
handheld, no electricity/power supply required)
target use(s) testing patient with stI 
Reference technology Laboratory-based NAAT
Performance Minimal Optimal
Clinical sensitivity† >90% (LL>90%) (genital) 100% (genital)
Clinical specificity 98% (LL>95%) (genital) 100% (genital)
Quantitation‡ Not applicable
Key minimal and optimal operational characteristics for chlamydial infection test
Minimal Optimal
Specimen§ First-catch urine =2 hours since last 
void (all persons), healthcare worker-
collected vaginal swab
Any urine (all persons), self-collected vaginal swab
Specimen preparation Minimal sample processing; no more 
than one operator step
Integrated
Steps performed by healthcare worker between 
specimen preparation and result
No more than three operator steps 
that are not timed nor labour 
intensive
One operator step (none of which has a timed interval), excluding waste disposal
Time to result =60 min =30 min
Connectivity: device/reader If combined with a reader, reader has 
integrated GPS module.
If combined with a reader, internally integrated GPS/GPRS module and conformity with 
HL-7 messaging standards
Data export (for quality assurance): device/reader If combined with a reader, full data 
export over mobile phone network
 ► If combined with a reader, full data export over mobile phone network (data 
transmission can automatically select between GPRS or more advanced networks 
and GSM, based on available coverage).
 ► GPRS should be able to use the internet FTP to transmit data: data transfer should 
be initiated every 6–12 hours automatically by the reader; data can be exported 
in a format compatible with HL-7 standards, where appropriate; instrument tracks 
and transmits quality assurance data over time (eg, identify shifts or trends).
Target price per test (excluding the cost of a 
device or reader)¶
<US$5 <US$1
*Should be guided by the knowledge of the local epidemics.
†Based on a sample size sufficient to achieve CIs of ±5% around a point estimate of sensitivity and specificity.
‡POCTs are only to provide a positive/negative result, other quantitative methods will be used for quantitation.
§Sensitivity and specificity for rectal and pharyngeal swabs are not yet determined.
¶It does not include the cost of device/reader in case the POCT is device based or/and requires a reader for the result.
CT, Chlamydia trachomatis; FTP, File Transfer Protocol; GPRS, General Packet Radio Service; GPS, Global Positioning System; GSM, Global System for Mobile; MSM, men who have 
sex with men; POCT, point-of-care testing; SW, sex worker; TPP, target product profile.
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Other promising technological developments
Other promising technologies include electrochemical 
approaches, although they are limited to enzymes and reagents 
that are capable of producing an electrochemical signal. For 
example, Aalto Bio Reagents is developing a unique lab-on-a-
chip technology that uses an electrochemical immunoassay 
technology with an immune-electrode detector to produce a 
sample-to-answer result from a patient specimen in less than 
15 min.
Finally, other non-optical approaches may detect mass or 
mechanical forces. The potential downside is that mechanical 
sensors may not be robust enough for handheld diagnostic test 
platforms. In addition, thanks to improved microfabrication 
techniques, innovative approaches are being made possible by 
increasingly miniaturised measurement techniques that have the 
potential to be used in diagnostics. For example, mass spectrom-
etry has already been miniaturised and coupled with microflu-
idic devices.45
In summary, some next-generation technologies appear to 
have promising applications for diagnostics at POC, but to date 
few of them have been  commercialised.iii In addition, there is 
a long and arduous road from demonstrating the use of these 
technologies either for enrichment of a biological sample or 
the sensitive detection of an analyte to a combined sample-in, 
result-out diagnostic platform. The integration of these tech-
niques is a big challenge, but only when all components of a 
test have been combined into a self-contained device that can be 
used at POC can new technologies realise their full promise for 
improving global health.
dIscussIOn And cOnclusIOns
Because of the generally good performance of syphilis POCTs, 
there is arguably no need for additional mono tests. However, 
there are several important needs for new syphilis dual tests, 
preferably in the form of POCTs, in resource-limited settings. 
One of these is for a combination TP/non-TP test that can be 
used to diagnose syphilis, and preferably differentiate active 
syphilis at the POC where traditional laboratory-based testing 
may not be available. Another need is for HIV/syphilis dual as 
well as HIV/syphilis/hepatitis B virus (HBV) tests. The latter is 
needed to support the current efforts for the triple elimination of 
vertical transmission of HBV, syphilis and HIV,14 requiring strong 
screening components for all three infections.
With respect to other STIs, there are reasonably robust molec-
ular platforms for which assays for CT, NG, TV and HPV are 
currently being developed. One platform, from Cepheid, already 
provides assays for CT, NG, CT/NG, TV and HPV. Other plat-
forms designed for use at or near the point of patient care will 
have similar capabilities. However, a number of these platforms 
are more appropriate for use at the district hospital level or above 
in resource-limited settings. This offers some degree of test decen-
tralisation and should help increasing access to testing, but in order 
to truly expand access and reach more patients, it will be necessary 
iii See Sharma et al for a list of FDA-approved microfluidic-based tests for 
use at the point of care.(63) The list includes platforms from Alere, BD, 
Abbott and Roche.
table 8 POCTs—TV: summary of selected analytical and operational characteristics
Company Cepheid Quidel Atlas Genetics
Assay name GeneXpert AmpliVue Atlas io (pipeline)
Use setting Tabletop; not portable
Level 2
Tabletop; not portable
Level 2; need heat block; vortex 
Tabletop; portable
Level 1
Specimen Female and male urine, endocervical swab/
patient-collected vaginal swab
Vaginal swabs from symptomatic and asymptomatic 
women
Self-collected and clinician-collected 
vaginal swabs from symptomatic and 
asymptomatic women, and urine from 
men
Steps ~4; sample preparation automated Moderately complex; ~12 steps; timed incubation ~4; automated sample preparation on 
instrument
Time to result ~60 min 45 min 30 min
Cold chain; reagent stability Kit storage: 2°C–28°C Cartridge/cassettes: 2°C–30°C; buffers: 2°C–8°C Cartridges with reagents stable at 
2°C–25°C
Power Mains power required; can use solar Mains power required for heat block Mains power required
Training Less than 0.5 day Less than 0.5 day Less than 1 hour; no formal training 
required; self-explanatory user guide and 
screens on instrument
Connectivity Yes; computer/internet required; remote 
calibration
No Yes; via middleware
Equipment cost (US$); per 
test
~$17 000 (with 4 modules), but could be 
higher; $19.00
TBD TBD
Level 1=primary healthcare centre. Level 2=district hospital.
POCT, point-of-care testing; TBD, to be determined; TV, Trichomonas vaginalis.
table 9 Analytical and operational characteristics of the Cepheid 
HPV assay
Company Cepheid
Use setting Tabletop; not portable
Level 2
Specimen Female endocervical swab
Training Less than 0.5 day
Time to result ~60 min
Power Mains power required
Connectivity Yes; computer/internet required; remote calibration
Equipment cost (US$); per test ~US$17 000 (with 4 modules), but could be higher; 
$16.70
Level 2=district hospital.
HPV, human papillomavirus; TBD, to be determined.
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to locate test platforms at the primary healthcare level where labo-
ratories are often quite basic.
Despite the current pipeline for POC STI platforms, there is still a 
need to develop tests that can be effectively used at primary health-
care centres in resource-constrained settings with which test results 
can be provided to patients to inform clinical care at a single visit. 
The impact of these increasingly sophisticated diagnostic technol-
ogies will be limited unless they can successfully accommodate the 
weaknesses in healthcare systems in resource-constrained settings, 
which often affect the successful delivery of diagnostics in-country. 
These include: shortages of human resources and lack of training 
for staff; supply chain challenges; lack of diagnostic equipment and 
equipment breakdowns; and a lack of robust quality assurance and 
quality control systems.
These weaknesses suggest the need for training of test oper-
ators and service and maintenance contracts for diagnostics, 
and that the following operational specifications for POC 
diagnostic assays/platforms should be prioritised: (1) ease of 
use; (2) training; (3) high tolerance to difficult environmental 
conditions and high shelf life; (4) self-contained quality control; 
(5) data capture/connectivity/data export; (6) biosafety; and (7) 
waste disposal. In addition, other specifications must also be 
emphasised. These include cost, sample capacity/throughput and 
time to result.
These factors, along with required technical performance, 
must be considered and prioritised by developers of diagnostics 
intended for use at POC in resource-limited settings. The TPPs 
for STI POCTs aim to guide future development. The targets 
of clinical sensitivity and specificity of POCTs across all TPPs 
address the needs for differentiating between screening, case 
finding and STI surveillance. This should permit an appropriate 
trade-off throughout all stages of the POCT pipeline—devel-
opment, validation and implementation. The targets of perfor-
mance and other parameters range from minimal to optimal, 
table 10 TPP—combined/mono-HPV DNA or RNA test
Goal of test To detect clinically relevant (=1.0 pg/mL) high-risk HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), HPV DNA 
or RNA; correlated with CIN3+
Intended use and target patient* Screening: women aged 30–64 years or HIV-positive women at any age
Target use setting To detect clinically relevant (=1.0 pg/mL) high-risk HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68), HPV DNA 
or RNA; correlated with CIN3+
Results Clear positive, negative or invalid result with minimal instructions for interpretation
Equipment Single-use, biodegradable or recyclable disposable diagnostic test preferred, reader optional (small, portable, tabletop or 
handheld, no electricity/power supply required)
target use(s)
Reference technology Laboratory-based NAAT
Performance Minimal Optimal
Clinical sensitivity† 85% 95%
Clinical specificity ‡
Quantitation§ Not applicable
Key minimal and optimal operational characteristics for hPV dnA or rnA test
Minimal Optimal
Specimen Provider-collected cervical specimen and self-
collected cervicovaginal specimen (preferred 
because no need for speculum exam or clinic visit)
Provider-collected cervical specimen and self-collected cervicovaginal 
specimen (preferred because no need for speculum exam or clinic visit)
Steps performed by healthcare worker between 
specimen preparation and result
No more than three operator steps that are not 
timed nor labour intensive
Maximum one operator step (none of which has a timed interval), 
excluding waste disposal
Training required <90 min 30 min
Time to result =60 min =30 min
Regulatory requirements Compliance with appropriate ISO standard
Connectivity: device/reader If combined with a reader, reader has integrated 
GPS module.
If combined with a reader, internally integrated GPS/GPRS module and 
conformity with HL-7 messaging standards
Data export (for quality assurance): device/reader If combined with a reader, full data export over 
mobile phone network
 ► If combined with a reader, full data export over mobile phone 
network (data transmission can automatically select between GPRS 
or more advanced networks and GSM, based on available coverage).
 ► GPRS should be able to use the internet FTP to transmit data: data 
transfer should be initiated every 6–12 hours automatically by the 
reader; data can be exported in a format compatible with HL-7 
standards, where appropriate; instrument tracks and transmits 
quality assurance data over time (eg, identify shifts or trends).
Target price per test (excluding the cost of a 
device or reader)¶
<US$3 <US$1.5
Link to full target product profile—combined/mono-HPV DNA or RNA test
∗Should be guided by the knowledge of the local epidemics.
†Based on a sample size sufficient to achieve CIs of ±5% around a point estimate of sensitivity and specificity.
‡Values are currently under revision.
§POCTs are only to provide a positive/negative result, other quantitative methods will be used for quantitation.
¶It does not include the cost of device/reader in case the POCT is device based or/and requires a reader for the result.
FTP, File Transfer Protocol; GPRS, General Packet Radio Service; GPS, Global Positioning System; GSM, Global System for Mobile; HPV, human papillomavirus; ISO, International 
Organization for Standardization; POCT, point-of-care testing; TPP, target product profile.
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giving the necessary space for manoeuvring between implemen-
tation of existing tests (minimal) and development of new tests 
(optimal). It is only when the required technical specifications 
and preferred operational specifications are integrated into a 
single platform that new tests for STIs will be well positioned to 
achieve the desired level of uptake and impact on global health.
The absence of representatives from manufacturers in the 
consultation process could be considered a limitation, particu-
larly with regard to the operational characteristics of desired 
POCTs. This was counterbalanced by the large spectrum of 
expertise in different fields and from various geographical 
areas in our consultative group. As the field of POCTs is both 
constantly evolving and dispersed, it is possible that some prom-
ising technologies have been unintentionally omitted.
Notwithstanding these limitations, the landscape analysis and 
TPPs inform both the development of new diagnostic platforms 
and support the validation and implementation of the existing 
diagnostic tests positioned by the manufacturers as POC or 
near-to-patient tests. Regular updates of TPPs and reviews of 
the diagnostic landscape for targeted STIs should continue to 
be integral parts of this process. Guiding developers, producers, 
researchers and implementers on the critical parameters of the 
desired POCTs and including industry, researchers, clinicians, 
policymakers, donors and affected populations will help reduce 
the gaps between the current and future diagnostic technologies 
and public health needs.
Key messages
 ► The target product profiles and landscape analysis 
contribute to the global efforts to accelerate access to 
reliable and affordable point-of-care testing (POCT) through 
standardisation of requirements of diagnostic assays.
 ► Both documents are dynamic and should be regularly 
updated using a multidisciplinary and multistakeholder 
approach, ensuring buy-in and common understanding of the 
main outcomes.
 ► Further engagement of representatives of both the field 
and manufacturers is critical for setting up realistic and 
achievable goals for POCTs of interest.
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